Publicaciones en colaboración con investigadoras/es de Instituto de Investigación Sanitaria Biocruces Bizkaia (44)

2024

  1. Effect of antipsychotic drugs on group II metabotropic glutamate receptor expression and epigenetic control in postmortem brains of schizophrenia subjects

    Translational Psychiatry, Vol. 14, Núm. 1

  2. Effects of cannabidiol in post-stroke mood disorders in neonatal rats

    Pediatric Research

  3. Exploring the reactivity of bicyclic α-iminophosphonates to access new imidazoline I2 receptor ligands

    Bioorganic Chemistry, Vol. 142

  4. Next-Generation Proteomics of Brain Extracellular Vesicles in Schizophrenia Provide New Clues on the Altered Molecular Connectome

    Biomedicines, Vol. 12, Núm. 1

2023

  1. Ethanol and illicit drugs acute use and abuse as risk factors for suicide: A case–control study based on forensic autopsies in the Basque Country, Spain

    Revista de Psiquiatria y Salud Mental

  2. Isolation and Differentiation of Neurons and Glial Cells from Olfactory Epithelium in Living Subjects

    Molecular Neurobiology, Vol. 60, Núm. 8, pp. 4472-4487

  3. Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer’s Disease

    Pharmaceutics, Vol. 15, Núm. 10

  4. The Matricellular Protein Hevin Is Involved in Alcohol Use Disorder

    Biomolecules, Vol. 13, Núm. 2

  5. The Role of the Dopamine System in Post-Stroke Mood Disorders in Newborn Rats

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

2022

  1. Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients

    Addiction Biology, Vol. 27, Núm. 6

  2. Glutamate, Glutamatergic Drugs and Schizophrenia

    Glutamate and Neuropsychiatric Disorders: Current and Emerging Treatments (Springer International Publishing), pp. 493-521

  3. NRN1 Gene as a Potential Marker of Early-Onset Schizophrenia: Evidence from Genetic and Neuroimaging Approaches

    International Journal of Molecular Sciences, Vol. 23, Núm. 13

2021

  1. Characterization of Hevin (SPARCL1) Immunoreactivity in Postmortem Human Brain Homogenates

    Neuroscience, Vol. 467, pp. 91-109

  2. Characterization of dopamine D2 receptor coupling to G proteins in postmortem brain of subjects with schizophrenia

    Pharmacological Reports, Vol. 73, Núm. 4, pp. 1136-1146

  3. Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia

    Neuropsychopharmacology, Vol. 46, Núm. 3, pp. 665-672

  4. Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment

    Translational Psychiatry, Vol. 11, Núm. 1

  5. Opposite alterations of 5­HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile

    Translational Psychiatry, Vol. 11, Núm. 1

  6. Oral and Palmitate Paliperidone Long-Acting Injectable Formulations' Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP)

    International Journal of Neuropsychopharmacology, Vol. 24, Núm. 9, pp. 694-702

  7. Spinophilin expression in postmortem prefrontal cortex of schizophrenic subjects: Effects of antipsychotic treatment

    European Neuropsychopharmacology, Vol. 42, pp. 12-21

  8. Subcellular specificity of cannabinoid effects in striatonigral circuits

    Neuron, Vol. 109, Núm. 9, pp. 1513-1526.e11